MichaelJamesBaineMDPhD

Radiation Oncology • Omaha, NE

Urologic Cancer

Associate Professor and Medical Director

Join to view full profile

Dr. Baine is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Baine's full profile

Already have an account?

Office
505 S 45th St
Omaha, NE 68198
Phone+1 402-559-5600

Summary

I am a member of the Department of Radiation Oncology at the University of Nebraska Medical Center, acting in a physician scientist role. My clinical practice is focused on GU malignancies with my lab investigating pancreas, prostate, and bladder cancers. I have specific interests in radiomics, ultrahypofractionated radiation treatment for prostate, body SBRT for oligometastatic diseases, and the interactions between high dose-per-fraction radiation treatments and the immune system with the hope of leveraging this into greater efficacy of immunotherapy.

Education & Training

University of Nebraska Medical Center College of MedicineResidency, Radiation Oncology, 2015 - 2019
University of Nebraska Medical Center College of MedicineInternship, Internal Medicine, 2014 - 2015
University of Nebraska College of Medicine

Certifications & Licensure

IA State Medical License 2019 - 2026
NE State Medical License 2019 - 2026
American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

Sigma Xi 2022
Alpha Sigma Nu Loyola Marymount University, 2006
Inductee Alpha Omega Alpha Honor Medical Society

Clinical Trials

Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer Start of enrollment: 2016 Sep 16
Recruiting
Phase 2
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer Start of enrollment: 2019 Jun 03
Active, not recruiting
Phase 3
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial Start of enrollment: 2020 Dec 15
Recruiting
Phase 3
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score Start of enrollment: 2021 Nov 03
Recruiting
Phase 3
High-dose Brachytherapy Boost With Stereostatic Body Radiation Therapy to Intermediate or Higher Risk Prostate Cancer Start of enrollment: 2023 Aug 29
Recruiting
Not Applicable
Join now to see all

Publications & Presentations

PubMed

Role of immunotherapy in the overall survival of gastrointestinal cancer patients with liver metastases.
Taoyuan M Beninato, Saber A Amin, Michael J Baine, Chi Lin
Hepatic Oncology. 2024-12-31
Heme Oxygenase-1 and Prostate Cancer: Function, Regulation, and Implication in Cancer Therapy.
Ramia J Salloom, Iman M Ahmad, Dania Z Sahtout, Michael J Baine, Maher Y Abdalla
International Journal of Molecular Sciences. 2024-08-24
1 citations
Exogenous APN protects normal tissues from radiation-induced oxidative damage and fibrosis in mice and prostate cancer patients with higher levels of APN have less rad...
Joshua A McDowell, Elizabeth A Kosmacek, Michael J Baine, Oluwaseun Adebisi, Cheng Zheng
Redox Biology. 2024-07-01

Press Mentions

The Impact of Neoadjuvant and Adjuvant Immunotherapy on the Survival of Pancreatic Cancer Patients: A Retrospective AnalysisJune 9th, 2020
The Impact of Immunotherapy on the Survival of Pancreatic Adenocarcinoma Patients Who Received Definitive Surgery of the Pancreatic Tumor: A Retrospective Analysis of the National Cancer DatabaseJune 3rd, 2020

Professional Memberships